Gene:
GIPR
gastric inhibitory polypeptide receptor

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for GIPR

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
rs10423928 NC_000019.10:g.45679046T>A, NC_000019.9:g.46182304T>A, NM_000164.3:c.1152+820T>A, NM_001308418.1:c.1044+820T>A, XM_005258733.1:c.1044+820T>A, XM_011526709.1:c.1278+820T>A, XM_011526710.1:c.1278+820T>A, XM_011526711.1:c.1170+820T>A, XM_011526712.1:c.1044+820T>A, XM_011526713.1:c.1029+820T>A, XM_011526714.1:c.861+820T>A, XM_011526715.1:c.861+820T>A, XR_935791.1:n.1171+820T>A
T > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  None
Alternate Symbols:  None
PharmGKB Accession Id: PA28682

Details

Cytogenetic Location: chr19 : q13.32 - q13.32
GP mRNA Boundary: chr19 : 46171490 - 46185717
GP Gene Boundary: chr19 : 46161490 - 46188717
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Curated Information ?

Publications related to GIPR: 6

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A missense variant in GLP1R gene is associated with the glycemic response to treatment with gliptins. Diabetes, obesity & metabolism. 2016. Javorský Martin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers. Pharmacogenomics. 2016. Tkáč Ivan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH): Design of a pharmacogenetic Resource for Type 2 Diabetes. PloS one. 2015. Walford Geoffrey A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
GIPR Gene Polymorphism and Weight Gain in Patients With Schizophrenia Treated With Olanzapine. The Journal of neuropsychiatry and clinical neurosciences. 2015. Ono Shin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine. The pharmacogenomics journal. 2011. Ono S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nature genetics. 2010. Saxena Richa, et al. PubMed

LinkOuts

NCBI Gene:
2696
OMIM:
137241
UCSC Genome Browser:
NM_000164
RefSeq RNA:
NM_000164
RefSeq Protein:
NP_000155
RefSeq DNA:
NT_011109
UniProtKB:
GIPR_HUMAN (P48546)
Q4VBP1_HUMAN (Q4VBP1)
Ensembl:
ENSG00000010310
GenAtlas:
GIPR
GeneCard:
GIPR
MutDB:
GIPR
ALFRED:
LO000498V
HuGE:
GIPR
ModBase:
P48546
HumanCyc Gene:
HS00281
IUPHAR Receptor:
GIP (248)
HGNC:
4271

Common Searches